Skip to content
DataLookout
Menu

NCT07905924

A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) Mutation

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Parts 1A and 1B: Incidence and Severity of Adverse Events (AEs)
Timeframe: From first dose up to approximately 5 years
Part 2: Incidence and Severity of AEs
Timeframe: From first dose up to approximately 5 years
Parts 3A, 3B and 3C: Incidence and Severity of AEs
Timeframe: From first dose up to approximately 5 years
Parts 1A and 1B: Incidence of Dose-limiting Toxicities (DLTs)
Timeframe: From Cycle 1 Day 1 (C1D1) until C1D21 (Cycle 1 = 21 days)
Part 3A: Incidence of DLTs
Timeframe: From C1D1 until C1D21 (Cycle 1 = 21 days)
Parts 3B and 3C: Incidence of DLTs
Timeframe: From C1D1 until C1D28 (Cycle 1 = 28 days)
Parts 1A and 1B: Recommended Dose for Expansion (RDE) of RO7836748 Monotherapy
Timeframe: Up to approximately 5 years
Parts 3A, 3B, 3C: RDE of RO7836748 in Combination With Other Anti-Cancer Therapies
Timeframe: Up to approximately 5 years

Secondary (7)

Parts 1A, 1B and 2: Plasma Concentrations of RO7836748 and its Metabolites as Monotherapy
Parts 3A, 3B and 3C: Plasma Concentrations of RO7836748 and its Metabolites in Combination With Other Anti-Cancer Therapies.
All Parts: Objective response rate (ORR)
All Parts: Duration of response (DoR)
All Parts: Disease control rate (DCR)
Show 2 moreShow less
All Parts: Progression-free survival (PFS)
All Parts: Overall survival (OS)

Arms and interventions

Part 1A: RO7836748 Monotherapy (Dose Escalation)Experimental

Participants with advanced solid tumors (second line or higher \[2L+\]) with a RAS G12V mutation will receive increasing doses of RO7836748.

Part 1B: RO7836748 Monotherapy Backfill CohortsExperimental

Participants with (2L+) NSCLC, PDAC, and CRC with a RAS G12V mutation will receive the selected doses of RO7836748 at sponsor's discretion Some participants enrolled may also participate in a food effect assessment and/or a drug-drug interaction (DDI) investigation, if necessary.

Part 2: RO7836748 Monotherapy (Dose Expansion)Experimental

Participants with 2L+ NSCLC, PDAC, and CRC with a RAS G12V mutation will receive RO7836748 at the dose selected based on findings from Part 1A and 1B.

Part 3A: RO7836748 + Pembrolizumab (Dose Escalation and Randomized Expansion)Experimental

Participants with untreated advanced (first line treatment \[1L+\]) or metastatic NSCLC with a KRAS G12V mutation and programmed death-ligand (PD-Ll ) tumor cell expression levels ≥ 1% will receive RO7836748 in combination with pembrolizumab at the dose selected based on findings from Parts 1 and 2.

Part 3B: RO7836748 + mFOLFIRINOX (Dose Escalation and Randomized Expansion)Experimental

Participants with untreated advanced (1L) or metastatic PDAC will receive RO7836748 in combination with mFOLFIRINOX at the dose selected based on findings from Parts 1 and 2.

Part 3C: RO7836748 + Cetuximab (Dose Escalation and Randomized Expansion)Experimental

Participants with CRC after second line/ third line (2L/3L) treatment will receive RO7836748 in combination with cetuximab at the dose selected based on findings from Parts 1 and 2.

Drugs: RO7836748, Pembrolizumab, mFOLFIRINOX, Cetuximab